A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 60, Issue 10, 1999, Pages 658-663

  Ho, Beng Choon ^a,b   Miller, Del ^a   Nopoulos, Peg ^a   Andreasen, Nancy C ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0032695046     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1003     Document Type: Article

References (30)

1. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
3. Peuskens J, for the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
4. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
5. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-167
6. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
7. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697
8. Flaum MA, Andreasen NC, Arndt S. The Iowa Prospective Longitudinal Study of Recent-Onset Psychoses. Schizophr Bull 1992;18:481-490
9. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-623
10. Andreasen NC. PSYCH-BASE. Iowa City, Iowa: The University of Iowa; 1989
11. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: The University of Iowa; 1983
12. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: The University of Iowa; 1984
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-99
14. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(suppl):11-19
16. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
17. Conover WJ. Practical Nonparametric Statistics. New York, NY: John Wiley & Sons; 1980
18. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1981;35:124-133
19. Ho BC, Andreasen N, Raum M. Dependence on public financial support early in the course of schizophrenia. Psychiatr Serv 1997;48:948-950
20. Hogarty GE, Schooler NR, Baker RW. Efficacy versus effectiveness [editorial]. Psychiatr Serv 1997;48:1107
21. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
22. Schooler NR. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [letter]. J Clin Psychopharmacol 1998;18: 174-175
23. Tollefson GD, Tran PV. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [reply letter]. J Clin Psychopharmacol 1998;18:175-176
24. Gheuens J, Grebb JA. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [letter]. J Clin Psychopharmacol 1998;18:176-177
25. Tollefson GD, Tran PV. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [reply letter]. J Clin Psychopharmacol 1998;18:177-178
26. Kasper S, Kufferle B. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [letter]. J Clin Psychopharmacol 1998;18:353-354
27. Tollefson GD, Tran PV. Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [reply letter]. J Clin Psychopharmacol 1998;18:354-355
28. Conley R, Kelly D, Love R. Risperidone use in Maryland: dosing trends and rehospitalization rates. Biol Psychiatry 1998;43:119S-120S
29. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201
30. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10:55-72